Navigation Links
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
Date:3/19/2009

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

The trial is being conducted at approximately 45 hospital sites across the U.S. and has enrolled 600 patients undergoing open colorectal surgery, which is widely considered to be the most prone to surgical site infection (SSI). Patients in the treatment group have two Gentamicin Implants (260 mg total dose) implanted in the wound before abdominal closure and the primary endpoint is total incidence of SSI after 2 months post-surgery. The design of the trial is based upon an approved and well established use of GENTAMICIN SURGICAL IMPLANT for this indication in Europe. The results of several such studies have been published, including one prospective, randomized, controlled clinical trial in 221 patients which demonstrated a 70 percent decrease in surgical site infections from 18.4 percent in the control group to 5.6 percent in the patients treated with the implant.

Patient enrolment in the first phase 3 trial being conducted in diabetic and/or obese patients undergoing cardiac surgery closed earlier this month. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Coordinating Center for both phase 3 trials.

Dr. Michael Myers, Innocoll's President and CEO commented, "Having recently completed patient enrollment in our first phase 3 trial in cardiac surgery, we are pleased to have now concluded enrollment in both trials, which FDA has confirmed are the only trials we need for NDA approval. As a well established product in Europe and other non-U.S. markets with proven safety, efficacy and pharm
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
11. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... OTEMR, Inc. , ONETOUCH EMR, 2.0 has achieved ONC ... the software is capable of supporting eligible providers with ... measures required to qualify for funding under the American ... certified on July 14, 2014 by ICSA Labs ... (ONC-ACB) and is compliant in accordance with applicable criteria ...
(Date:9/17/2014)... , Sept. 17, 2014  Members of ... and Interventional Associates announced today that the ... to enhance its image sharing capabilities and provide ... any network failures. In addition, the Dicom Systems ... navigate disparate PACS systems to more effectively deliver ...
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3New Product from Vireo Systems: pH-D Feminine Health Support 2
(Date:9/17/2014)... The Food and Drug Administration (FDA) has ... consider: , 1. The appropriate indicated ... 2. The potential for adverse cardiovascular outcomes associated ... ongoing, an informally-organized litigation group subcommittee prepared a presentation ... therapy. Among others, ZKB attorney Michelle L. Kranz and ...
(Date:9/17/2014)... September 17, 2014 StartX , ... 12 companies raising rounds of funding at its Summer ... hundred investors and media, was the first such gathering ... next to the university. The presentations were delivered on ... to StartX-QB3 Labs, a 2,000 square foot life science ...
(Date:9/17/2014)... 2014 Cadiz Laser Spa offers ... procedures to clients throughout Central Texas. The newest ... Collagen Induction Therapy. Using the revolutionary Rejuvapen micro-needling ... help clients correct a wide variety of skin ... and Cadiz Laser Spa is currently offering a ...
(Date:9/17/2014)... News) -- Present-day Europeans are the descendants of ... to a new study. Previous research ... early European farmers. But, a new genetic analysis ... the descendants of Ancient North Eurasians. Nearly all ... ancestral group, researchers from Harvard Medical School said. ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... uncovered a key factor to explain why antibiotic-resistant bacteria can ... DNA called plasmids appear to be the culprit. They can ... and some carry a gene that makes bacteria drug-resistant, a ... carry an antibiotic-resistant gene to a class of antibiotic called ...
Breaking Medicine News(10 mins):Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3
... new study has revealed that women diagnosed with breast ... exercise , then they should continue exercising, for ... ,Ohio State University researchers analysed 500 women, who had ... and more specifically the intensity and amount of physical ...
... smoking, by finding that regular smokers may have a higher ... never smoke. ,The study also found that while smokers ... in short run, this risk declines to the level of ... other words, both completely smoke-free life style and successful smoking ...
... is the biggest environmental issue no one's talking about," regrets ... founder of the Work Less Party, a Vancouver-based initiative aimed ... "As a society, we're working exponentially hard to decrease sustainability ... antidepressants are on the rise," he says. ,Americans ...
... it doesnt have to be that way always. ... that they have successfully managed to reduce wrinkles ... vitamin A. ,Not only did the cream ... people revealed it boosted levels of important skin repair ...
... an otherwise bleak healthcare scenario has emerged a heartening ... IM injection manufactured by the US based Institute for ... its Model List for Essential Medicines. ,Paromomycin ... (VL), the worlds second most deadly parasitic disease after ...
... prefer not to talk about, yet sufferers will go to ... overactive bladder (OAB) and it's characterized by a sudden ... ,Now, to reduce the symptoms of OAB, an Emory ... ankle to better help control the bladder. ,"Known ...
Cached Medicine News:Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Work Less to Sustain Planet Earth, Say Activists 2Health News:Work Less to Sustain Planet Earth, Say Activists 3Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: